Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lifestyle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,315 result(s) found for: Lifestyle. Displaying page 3 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-002141-11 Sponsor Protocol Number: Vedolizumab-3035 Start Date*: 2018-11-08
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Und...
    Medical condition: Intestinal acute graft-versus-host disease (aGvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) DE (Completed) AT (Completed) PL (Completed) ES (Completed) PT (Completed) BE (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004023-20 Sponsor Protocol Number: MK-3475-992 Start Date*: 2020-02-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Pa...
    Medical condition: Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) IE (Completed) DK (Prematurely Ended) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004400-34 Sponsor Protocol Number: LTS15823 Start Date*: 2021-03-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (GZ/SAR402671) in patients at risk of rapidly progressiv...
    Medical condition: Congenital cystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010428 Congenital cystic kidney disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) NL (Completed) BE (Prematurely Ended) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-005028-11 Sponsor Protocol Number: I4V-MC-JAIM Start Date*: 2019-10-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) HU (Completed) PL (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) NL (Completed) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018437-21 Sponsor Protocol Number: LANTU_C_03680 Start Date*: 2010-06-07
    Sponsor Name:SANOFI AVENTIS GROUPE
    Full Title: A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated ...
    Medical condition: Type 2 diabetes not adequately controlled
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IE (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) FR (Completed) NL (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002794-51 Sponsor Protocol Number: CLMF237A2302 including amd 2 Start Date*: 2006-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, active-controlled, multicentre study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monothe...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-003367-26 Sponsor Protocol Number: MK4482-001 Start Date*: 2020-11-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003368-24 Sponsor Protocol Number: MK-4482-002 Start Date*: 2020-11-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003518-14 Sponsor Protocol Number: SKY2028-3-003 Start Date*: 2006-01-25
    Sponsor Name:Skyepharma AG
    Full Title: Long-term Open-label Safety Study with SKP Flutiform HFA pMDI (100/10μg and 250/10μg) in Adult and Adolescent Patients with Asthma
    Medical condition: Mild to Moderate-Severe Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022382-10 Sponsor Protocol Number: CCX114151 Start Date*: 2011-01-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn’s Disease
    Medical condition: Subjects with Moderately-to-Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) CZ (Completed) SE (Prematurely Ended) NO (Completed) BE (Completed) DK (Completed) HU (Completed) IT (Completed) SK (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002216-52 Sponsor Protocol Number: MK-6482-012 Start Date*: 2021-04-13
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with...
    Medical condition: Clear cell renal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073251 Clear cell renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) IE (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004034-38 Sponsor Protocol Number: MK-7684A-002 Start Date*: 2021-04-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-...
    Medical condition: Non Small Cell Lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003436-92 Sponsor Protocol Number: MK-6482-022 Start Date*: 2022-03-28
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Trea...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) ES (Temporarily Halted) FI (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006776-17 Sponsor Protocol Number: BCX9930-205 Start Date*: 2023-01-10
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst sponsored Study
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003029-11 Sponsor Protocol Number: 2012-489 Start Date*: 2012-09-10
    Sponsor Name:Steen Stender
    Full Title: Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT)
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10071235 Combined hyperlipidemia LLT
    15.0 10010331 - Congenital, familial and genetic disorders 10060754 Type IV hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001975-36 Sponsor Protocol Number: 201200197536 Start Date*: 2012-05-24
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: Evaluation on the efficacy of docosahexaenoic acid for the treatment of nonalcoholic fatty liver disease in children
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004199-12 Sponsor Protocol Number: RG_11-139vitd Start Date*: 2012-01-04
    Sponsor Name:University of Birmingham
    Full Title: An open label dose ranging study to optimise vitamin D levels prior to oesophagectomy
    Medical condition: perioperative inflammation in patients undergoing oesophagectomy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000397-19 Sponsor Protocol Number: Ctrl-DM2 Start Date*: 2014-09-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Effects of Combined Treatment of Surgery and Liraglutide on Glycemic Variability and Control in type 2 Diabetes Mellitus: The Ctrl-DM2 Study
    Medical condition: type 2 diabetes with morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015058-38 Sponsor Protocol Number: OR09/9018 Start Date*: 2010-10-22
    Sponsor Name:University of Leeds
    Full Title: Improving the outcome for patients after osteoporotic femoral fractures
    Medical condition: OSTEOPOROTIC FEMORAL FRACTURE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001176-30 Sponsor Protocol Number: 20167169 Start Date*: 2016-06-15
    Sponsor Name:Clinical Research Institute, HUCH Ltd.
    Full Title: Effects of PCSK9 inhibition by Evolocumab on postprandial lipid metabolism in type 2 diabetes
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 03:47:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA